Meyer Handelman Co. increased its holdings in shares of Zoetis Inc (NYSE:ZTS) by 24.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 11,828 shares of the company’s stock after purchasing an additional 2,328 shares during the period. Meyer Handelman Co.’s holdings in Zoetis were worth $852,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in ZTS. Shelton Capital Management bought a new stake in shares of Zoetis during the 2nd quarter worth $232,000. Arrowstreet Capital Limited Partnership bought a new position in Zoetis in the second quarter valued at about $917,000. Raymond James Financial Services Advisors Inc. raised its position in Zoetis by 51.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,041 shares of the company’s stock valued at $1,936,000 after purchasing an additional 10,539 shares during the last quarter. Scotia Capital Inc. raised its position in Zoetis by 1.5% in the second quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock valued at $601,000 after purchasing an additional 142 shares during the last quarter. Finally, Westwood Holdings Group Inc. bought a new position in Zoetis in the second quarter valued at about $2,550,000. Institutional investors and hedge funds own 93.73% of the company’s stock.
Zoetis Inc (NYSE:ZTS) opened at $72.35 on Monday. Zoetis Inc has a 1 year low of $52.00 and a 1 year high of $80.13. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The stock has a market capitalization of $35,260.00, a PE ratio of 38.08, a PEG ratio of 1.60 and a beta of 1.07.
Several research firms have commented on ZTS. Piper Jaffray Companies reiterated a “buy” rating and issued a $86.00 target price on shares of Zoetis in a research report on Thursday, January 18th. BMO Capital Markets set a $78.00 target price on Zoetis and gave the company a “hold” rating in a research report on Monday, January 22nd. Jefferies Group reiterated a “buy” rating and issued a $89.00 target price on shares of Zoetis in a research report on Tuesday, January 16th. Zacks Investment Research downgraded Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price for the company. in a research report on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 target price on Zoetis and gave the company a “buy” rating in a research report on Thursday, January 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $73.72.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.